Paul Tudor Jones Solid Biosciences Inc. Transaction History

Tudor Investment Corp Et Al

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$3.49 - $5.51 $136,483 - $215,479	-39,107 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.37 - $10.72 $210,004 - $419,227	39,107 New	39,107 $216,000
Q4 2020 Feb 16, 2021	SELL	$3.08 - $7.79 $60,118 - $152,053	-19,519 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$2.02 - $3.08 $5,950 - $9,073	-2,946 Reduced 13.11%	19,519 $40,000
Q2 2020 Aug 14, 2020	SELL	$2.1 - $3.42 $10,917 - $17,780	-5,199 Reduced 18.79%	22,465 $66,000
Q1 2020 May 15, 2020	SELL	$2.31 - $4.43 $5,770 - $11,066	-2,498 Reduced 8.28%	27,664 $66,000
Q4 2019 Feb 14, 2020	BUY	$2.82 - $12.9 $85,056 - $389,089	30,162 New	30,162 $134,000
Q3 2019 Nov 14, 2019	SELL	$4.33 - $11.64 $97,693 - $262,621	-22,562 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$4.6 - $10.13 $103,785 - $228,553	22,562 New	22,562 $130,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $36.5M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.